Eprenetapopt

Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance[1][2][3].

Product Specifications

CAS Number

[5291-32-7]

Product Name Alternative

APR-246; PRIMA-1Met

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Apoptosis; Autophagy; Ferroptosis; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Autophagy

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PRIMA-1Met.html

Purity

99.52

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C1C(COC)(CO)N2CCC1CC2

Molecular Formula

C10H17NO3

Molecular Weight

199.25

Precautions

H315, H319

References & Citations

[1]Peng X, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.|[2]Stuber G, et al. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. Mol Cancer. 2009 Mar 26;8:23.|[3]Sallman DA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021;39 (14) :1584-1594.